22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
07:00 , May 5, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: GD3 ganglioside; ST8 α-N-acetyl-neuraminide α-2,8-sialyltransferase 1 (ST8SIA1); prominin 1 (PROM1; CD133)

Cancer INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting GD3 ganglioside or its synthetic enzyme ST8SIA1 could help treat glioblastoma multiforme (GBM). In patients, tumor levels of GD3 ganglioside and ST8SIA1...
07:00 , Mar 18, 2013 |  BioCentury  |  Strategy

Japan's biggest biotech

Japanese pharmaceutical companies have historically been thought of as stodgy, insular and opaque, but that is changing fast. One year into the job, Kyowa Hakko Kirin Co. Ltd. 's CEO is building his company along...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Clinical News

Sarcoma vaccine: Phase II started

MabVax began a double-blind, U.S. Phase II trial to compare its subcutaneous sarcoma vaccine with adjuvant compared to adjuvant alone in 126 patients. MabVax licensed the vaccine from Memorial Sloan-Kettering Cancer Center (New York, N.Y.)...
07:00 , May 7, 2001 |  BioCentury  |  Strategy

Merck KGaA's cancer pipeline

Merck KGaA's cancer pipeline Partner Indication Description Phase Vaccines Theratope Biomira (BIOM) Breast cancer Synthetic mimic of the mucin-associated glycan epitope STn conjugated to a carrier protein III BLP25 Biomira (BIOM) Non-small cell lung cancer...
07:00 , Jul 29, 1996 |  BC Week In Review  |  Clinical News

ImClone regulatory update

IMCL received U.S. Patent No. 5,529,922 covering its BEC-2 therapeutic vaccine. BEC-2 is an anti-idiotypic monoclonal antibody designed to mimic GD3, a glycolipid (ganglioside) antigen found on the surface of a number of cancer cells....